Lung, breast, and non-prostate genitourinary (NGU) cancer treatments were the most exciting tracks due to the march towards personalised medicine and expanded immunotherapy options.
Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million.
Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program at the National Institutes of Health (NIH), tells pharmaphorum about the
An EU-funded project that aims to encourage the implementation of artificial intelligence-based personalised care for lung cancer patients – dubbed I3LUNG – has formally launched.<
Researchers at the Institute of Cancer Research (ICR) in London have designed a prototype test that they think could be used to predict which combinations are likely to work in cancer patie
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte